Tellgen

Tellgen Capital Intensity

The Capital Intensity Ratio of Tellgen (300642.SZ) as of Nov 21, 2026 is 565.32 %. In the previous year, Capital Intensity Ratio was 400.43 % — a change of 41.18% (higher).

Capital Intensity

565.32 %

YoY

41.18%

Last updated:

Capital Intensity Ratio of Tellgen is 2025 565.32 % . Capital Intensity Ratio of Tellgen was 2024 400.43 % . It decreases by 41.18% higher compared to the previous year.

The Tellgen Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
302.27 CNY
Jan 1, 2019
282.36 CNY
Jan 1, 2020
280.19 CNY
Jan 1, 2021
228.97 CNY
Jan 1, 2022
232.51 CNY
Jan 1, 2023
309.46 CNY
Jan 1, 2024
400.43 CNY
Jan 1, 2025
565.32 CNY
The Tellgen Capital Intensity history
YEARCapital IntensityYoY
565.32 %+41.18%
400.43 %+29.40%
309.46 %+33.09%
232.51 %+1.55%
228.97 %-18.28%
280.19 %-0.77%
282.36 %-6.59%
302.27 %-2.10%
308.75 %+109.64%
147.28 %+8.09%
136.26 %-0.44%
136.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Capital Intensity Ratio of Tellgen is 565.32 % in 2025.

Capital Intensity Ratio of Tellgen changed from 400.43 % to 565.32 %, representing a 41.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Tellgen since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Tellgen with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tellgen

All Key Metrics — Tellgen